| Similar Articles |
|---|
 |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it?   |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
October 21, 2010
Brian Orelli |
Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track. |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
The Motley Fool
November 24, 2010
Brian Orelli |
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. |
The Motley Fool
July 12, 2006
Brian Lawler |
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. |
The Motley Fool
October 22, 2009
Brian Orelli |
The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
The Motley Fool
February 12, 2009
Brian Orelli |
Cruising, but Ready to Take Off Genzyme's in wait-and-see mode. |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
July 23, 2009
Brian Orelli |
This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
October 27, 2010
Selena Maranjian |
When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders. |
The Motley Fool
March 2, 2004
David Nierengarten |
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
The Motley Fool
June 16, 2009
Brian Orelli |
Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs. |
The Motley Fool
April 16, 2004
Charly Travers |
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
The Motley Fool
March 3, 2009
Brian Orelli |
A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals. |
The Motley Fool
November 19, 2009
Brian Orelli |
This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
July 21, 2006
Stephen D. Simpson |
Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
November 30, 2009
Brian Orelli |
Making Money More Efficiently Drug companies shape up, and it shows in their margins. |
The Motley Fool
April 24, 2008
Brian Lawler |
FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
May 30, 2007
Brian Lawler |
Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
The Motley Fool
July 18, 2005
Stephen D. Simpson |
Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky. |
The Motley Fool
July 26, 2010
Jennifer Schonberger |
The S&P 500's Biggest Movers The index's most notable movers this week. |
The Motley Fool
April 26, 2007
Brian Lawler |
Genzyme Is Good The biopharma giant announced unexpectedly strong first-quarter results on the back of higher sales of recently launched compounds. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
The Motley Fool
August 3, 2010
Brian Orelli |
Drama Continues: What's Genzyme Worth to Sanofi? Just get on with it, Sanofi and Genzyme. How much is Genzyme worth? Whatever its board of directors is willing to let it go for. |
The Motley Fool
September 27, 2006
Brian Lawler |
Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share. |
The Motley Fool
February 4, 2008
Brian Lawler |
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. |
The Motley Fool
April 20, 2006
John Bluis |
Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management. |
The Motley Fool
November 17, 2009
Dave Mock |
A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst. |
